Ignite Creation Date:
2025-12-25 @ 4:35 AM
Ignite Modification Date:
2026-03-09 @ 11:22 AM
Study NCT ID:
NCT06984718
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-05-22
First Post:
2025-05-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
Sponsor:
Akeso
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-06-25
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2025-05-15
First Submit QC Date:
None
Study First Post Date:
2025-05-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-05-15
Last Update Post Date:
2025-05-22
Last Update Post Date Type:
ACTUAL